Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Status:
Completed
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore whether DMF (Dimethyl Fumarate) or MMF (monomethyl
fumarate) its main bioactive metabolite, is capable of entering the central nervous system in
SPMS patients that are being treated with Tecfidera®. PK samples (pharmacokinetics - or the
amount of study drug in blood) will be tested to compare with PK samples, the amount of study
drug, in spinal fluid (CSF).
Phase:
Phase 4
Details
Lead Sponsor:
Multiple Sclerosis Center of Northeastern New York